Minas I H, Jackson H J, Joshua S D, Burgess P M
Victorian Transcultural Psychiatry Unit, Melbourne, Australia.
Schizophr Res. 1990 Oct-Dec;3(5-6):321-7. doi: 10.1016/0920-9964(90)90017-2.
It has been suggested that the presence of depression is a major determinant of abnormal dexamethasone suppression in patients with schizophrenia. It has been reported that negative symptoms in patients with schizophrenia are associated with increased rates of nonsuppression. In this study of schizophrenic inpatients, the Dexamethasone Suppression Test (DST), depression and negative and positive symptom ratings were carried out in two phases of the acute episode, in the second week after administration to, and in the week prior to discharge from, hospital. There was no association between depression and cortisol nonsuppression or between negative and positive symptoms and cortisol nonsuppression either early or late in the acute episode. It is concluded that the DST has no clinical utility in identifying the non-melancholic depression which occurs commonly in schizophrenia.
有人认为，抑郁症的存在是精神分裂症患者地塞米松抑制异常的主要决定因素。据报道，精神分裂症患者的阴性症状与不抑制率增加有关。在这项针对精神分裂症住院患者的研究中，在急性发作的两个阶段、给药后第二周以及出院前一周进行了地塞米松抑制试验（DST）、抑郁以及阴性和阳性症状评分。在急性发作的早期或晚期，抑郁与皮质醇不抑制之间、阴性和阳性症状与皮质醇不抑制之间均无关联。得出的结论是，DST在识别精神分裂症中常见的非忧郁性抑郁症方面没有临床实用性。
